QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zeev Hed who wrote (980)	8/1/2000 1:28:15 PM
From: Ian@SI	Read Replies (1) of 1321

Z, That's only the chip stuff that gets shot for having the best earnings and outlook ever. :-((( Biotechs are still being rewarded for exceeding estimates. :-) Seriously, there's nothing cyclical about Macular Degeneration. There's no other treatment that's shown any effectiveness. And I think Galbraith stated his belief on CNBC this morning that QLT's got at least a 3-5 year lead over any potential, yet unproved competition. The company has been extraordinarily conservative with its guidance yet stated that they expect to reach $150M Visudyne sales during the first 12 calendar months of sales. You like arithmetic Zeev. Here's some Q numbers from the conference call. Net Sales (US $): $25.5M Mktg and Mf'g Costs: $18M Profits: $.7.5M Mfg Costs (Cdn $) $3.3M (About $2.25M US) QLT's Share of profits: $3.75M or $5.5M Cdn What earnings/share do you expect based upon the $150M sales? $200M sales??? Best regards, Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next